OncoMatch/Clinical Trials/NCT06898957
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
Is NCT06898957 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including YL201 and Tarlatamab for small cell lung cancer.
Treatment: YL201 · Tarlatamab · Atezolizumab · Durvalumab — The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV
Prior therapy
Must have received: platinum-based chemotherapy
progressed or recurred following at least 1 line of platinum-based anti-cancer therapy
Cannot have received: DLL3 targeted therapy
Prior delta-like ligand 3 (DLL3)...targeted therapy
Cannot have received: B7-H3 targeted therapy
Prior...B7 homolog 3 (B7-H3) targeted therapy
Cannot have received: topoisomerase I inhibitor
Prior exposure to topoisomerase I inhibitors
Cannot have received: antibody-drug conjugate
Exception: with topoisomerase I inhibitor payload
antibody-drug conjugate (ADC) with topoisomerase I inhibitor payload
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Orange County Lennar Foundation Cancer Center · Irvine, California
- Yale New Haven Hospital · New Haven, Connecticut
- Moffitt Cancer Center · Tampa, Florida
- Dana Farber Cancer Institute · Boston, Massachusetts
- Siteman Cancer Center · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify